Q-omics provides the consensus-scored TCERG1L-AS1 profile across patient tissues and cancer cell-line models. TCERG1L-AS1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TCERG1L-AS1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TCERG1L-AS1 RNA expression shows 9,097 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, THCA, and KIRP as cancer lineages where TCERG1L-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCERG1L-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCERG1L-AS1 survival associations across molecular data types. TCERG1L-AS1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCERG1L-AS1 RNA expression–survival associations across cancer types. High TCERG1L-AS1 expression shows unfavorable associations in UCS, LUSC and PRAD, but favorable associations in CESC, ACC and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for TCERG1L-AS1 RNA expression.
This table summarizes TCERG1L-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TCERG1L-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCERG1L-AS1 shows lower tumor expression in KICH, UCEC and PRAD and higher tumor expression in THCA, KIRP and KIRC. The THCA box plot shows higher TCERG1L-AS1 RNA expression in tumor versus normal tissue (log2 FC = +1.364, t-test p < 0.001).
This table shows molecular features associated with TCERG1L-AS1 in patient tissues and cancer cell lines. In patient samples, TCERG1L-AS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
